Somewhere in the last fifteen years, the cultural narrative around cosmetic injectables shifted from restraint to maximalism. The result is a generation of faces that read as 'done' even in still photography, and a growing concern within the medical community about the long-term consequences of repeated, escalating treatment of the same anatomy.
AHPRA's 2023 guidelines for medical practitioners performing cosmetic procedures explicitly require practitioners to assess whether a procedure is clinically indicated for the individual patient, to discourage unrealistic expectations, and to actively decline treatment when it would not be in the patient's best interest. The medical position is not 'sell what the patient asks for'. It is 'recommend what the anatomy actually needs'.
The myth
If a little works, a lot will work more. If a treatment is effective, more frequent sessions will accelerate the outcome. If a result looks good at one syringe, two will look better. If treating one zone gives a nice result, treating every zone will give a transformed face.
These statements feel intuitive, particularly when the cosmetic industry's algorithms reward visible change. They are not, however, supported by either the published aesthetic literature or by what a clinician with a decade of follow-up actually observes in their own patients.
The reality
Most aesthetic interventions sit on a non-linear dose-response curve. There is a clinical sweet spot beyond which additional product, additional units, or additional frequency does not improve the outcome. Past that point, it begins to distort it. Volume replacement treatments, deposited repeatedly in the same tissue plane, can migrate, form palpable irregularities, or alter facial proportion in ways that are difficult to undo. Neuromodulators given too frequently or in excessive doses can produce muscular compensation, brow heaviness, or flatness of expression that compromises rather than refreshes the face.
Several long-term clinical reviews have flagged the same pattern: complications and patient dissatisfaction with cosmetic injectables correlate more strongly with cumulative product load and treatment frequency than with the choice of any single product. The face you see at age 50 is shaped, in part, by the decisions made in your 30s and 40s. Restraint compounds. So does excess.
Less is, in this field, almost always more medicine.
Why escalation happens
Escalation rarely starts as a clinical decision. It usually starts as a perceptual one. As the face gradually adapts to its treated state, the patient stops seeing the change. The result begins to feel 'normal', and the desire is to do a little more. The next session is slightly bigger. Over years, the cumulative load is significant, even though each individual decision felt small.
Photo references also play a role. Comparing your face to images that may themselves be heavily edited or aggressively treated can shift the patient's internal benchmark away from a realistic baseline. A good consultation includes the practitioner naming this dynamic when it appears.
What the AHPRA framework requires
The AHPRA cosmetic guidelines require, among other things: a thorough consultation prior to any treatment; assessment of whether the procedure is clinically appropriate; informed consent that includes risks, alternatives and reasonable expected outcomes; screening for unrealistic expectations and for body dysmorphic disorder; and a documented cooling-off period of at least 7 days before major cosmetic surgical procedures (and aligning with conservative practice for non-surgical interventions). 'More because the patient asked' is not a clinical justification.
What 'enough' looks like in practice
- · The smallest intervention that achieves the goal, not the largest the budget allows.
- · Reviewing rather than topping up. Many decisions to retreat improve when given two or three more weeks.
- · Treating one priority zone well, before adding adjacent ones.
- · Sometimes nothing: a consultation in which the recommendation is to wait, focus on skin quality, or do less than you came in expecting.
- · An honest pause at the 3 to 5 year mark to look at where the face has moved, not just where it is today.
How to have this conversation with your clinician
A useful test, before any cosmetic treatment, is to ask your practitioner three questions. What problem are we solving with this treatment? What would happen if we did nothing for six months? Is there a less-invasive option, and what are the trade-offs? A clinician who welcomes these questions is one who is comfortable practising restraint.
Restraint is not a marketing position. It is a clinical position, supported by long-term outcomes data and by the consistent observation that the best-ageing faces tend to belong to the patients who, year after year, did slightly less than they could have.
All cosmetic procedures carry risks. A consultation with a registered medical practitioner is required prior to any treatment, and outcomes vary. This article is general information only and is not medical advice.